ascopubs.org

Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: A meta-analysis.

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant R…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...
MedPage Today

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says

The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable risk/benefit profile in gastric/gastroesophageal junction (GEJ) cancers with ...
Oncology Nurse Advisor

In ES-SCLC, Adding PD-1/PD-L1 Inhibitors to Platinum-Etoposide Consistently Improves Survival

SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.
Morningstar

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ...
Targeted Oncology

Checkpoint Inhibitors in Advanced Upper GI Cancers After 2024 FDA Shift

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
ascopubs.org

Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in triple-negative breast cancer: A focus on survival, metastasis, and recurrence.

Effect of multifunctional biocatalytic nanoenzyme AuC@SCOF-Mn on photodynamic-immunoactivation cascade response and antitumor efficacy in triple negative breast cancer. This is an ASCO Meeting ...